Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHYLLOCONTIN vs ACCURBRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sustained-release theophylline; nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase activator. Bronchodilation via relaxation of bronchial smooth muscle; also reduces airway hyperresponsiveness and inflammation.
Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.
Treatment of asthma (maintenance therapy),Chronic obstructive pulmonary disease (COPD) maintenance therapy
FDA-approved: Treatment of COPD exacerbations,Off-label: Acute asthma exacerbations
For chronic obstructive pulmonary disease and asthma: initial dose 225 mg orally twice daily; may increase to 450 mg twice daily. Based on theophylline, target serum concentration 5-15 mcg/m L.
Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.
Terminal elimination half-life: 3-8 hours in non-smoking adults; reduced to 1.5-5 hours in smokers; prolonged to 10-30 hours in heart failure or hepatic cirrhosis.
Terminal elimination half-life: 8-12 hours (healthy adults), prolonged to 15-20 hours in hepatic impairment. Clinical context: Supports twice-daily dosing in most patients.
Primarily hepatic via CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolites: 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid.
Ipratropium: minimally metabolized via hydrolysis and conjugation; Albuterol: primarily metabolized by catechol-O-methyltransferase (COMT) and sulfation.
Renal: approximately 10% unchanged; hepatic metabolism accounts for ~90% of clearance; metabolites eliminated renally.
Renal: 60-70% as unchanged drug; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Approximately 40-60% bound, primarily to albumin.
85-90% bound to albumin.
0.45 L/kg (range 0.3-0.7 L/kg), approximating total body water; increased in neonates and cirrhosis.
0.8-1.2 L/kg (wide distribution into tissues, including lungs).
Oral immediate-release: 96-100%; sustained-release: 90-100%; rectal: approximately 80-90%.
Oral: 60-80% (first-pass metabolism reduces bioavailability).
GFR < 30 m L/min: reduce dose by 50% and monitor serum levels; avoid use if possible due to accumulation risk.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing oral dose by 50% or extending interval due to accumulation of acetylcysteine metabolites.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B: reduce dose by 75%; Child-Pugh Class C: contraindicated. Monitor serum levels closely.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential increased exposure.
Weight-based dosing (theophylline): 10-16 mg/kg/day orally divided every 6-12 hours; individualize based on serum levels (target 5-10 mcg/m L). Use immediate-release formulations; sustained-release not recommended.
Inhalation: Infants and children: 1-2 m L of 20% solution or 2-4 m L of 10% solution nebulized three to four times daily. Oral: Not typically recommended for chronic use; for acetaminophen overdose, weight-based dosing is used.
Lower initial doses (e.g., 112.5 mg twice daily) due to decreased clearance; monitor serum levels and adjust to target 5-10 mcg/m L. Avoid in elderly with cardiac arrhythmias or seizures.
No specific dose adjustment; monitor for adverse effects such as bronchospasm or nausea. Use with caution in elderly with renal impairment (refer to renal adjustment).
No FDA boxed warning.
No FDA boxed warning exists for this combination product.
Narrow therapeutic index; monitor serum theophylline levels. Risk of toxicity (seizures, arrhythmias) at high doses. Caution in patients with peptic ulcer, seizure disorders, cardiac disease, hepatic impairment, or in elderly. Drug interactions (CYP1A2 inducers/inhibitors).
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), worsening of narrow-angle glaucoma, urinary retention, hypokalemia, and immediate hypersensitivity reactions.
Hypersensitivity to theophylline; pre-existing cardiac arrhythmias (unless appropriate monitoring); active peptic ulcer disease.
Hypersensitivity to ipratropium, albuterol, or atropine; history of anaphylaxis to soya lecithin or related food products; narrow-angle glaucoma; prostatic hyperplasia or bladder neck obstruction (relative).
Avoid high-protein or charcoal-broiled foods, as they can decrease theophylline levels. Caffeine-containing foods and beverages (e.g., coffee, tea, cola, chocolate) may increase theophylline levels and toxicity risk. Consistent dietary habits are important to maintain stable serum levels.
High-fat meals can increase absorption of theophylline; take on an empty stomach or with light snack for consistent effect. Avoid large amounts of charcoal-broiled foods as they may decrease drug levels. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) can potentiate side effects such as nervousness, tremor, and insomnia. Charbroiled meats and cruciferous vegetables (broccoli, Brussels sprouts) may induce metabolism and reduce effectiveness. Grapefruit juice may increase theophylline levels; avoid concurrent use.
Teratogenic risk profile: Theophylline (active ingredient in Phyllocontin) is Pregnancy Category C. First trimester: Limited data suggest no major teratogenic risk, but animal studies show potential fetal toxicity at high doses. Second and third trimesters: Theophylline crosses the placenta; fetal serum levels approximate maternal levels. Adverse effects include fetal tachycardia, jitteriness, and neonatal respiratory distress. Risk of neonatal apnea and withdrawal symptoms at delivery.
No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.
Lactation summary: Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 1-10% of maternal levels. Monitor infant for irritability, insomnia, and feeding difficulties. Generally considered compatible with breastfeeding if maternal levels are therapeutic; avoid high doses.
Not known if excreted in human breast milk. Caution advised; consider developmental benefits vs risks. M/P ratio not available.
Dosing adjustments in pregnancy: Pregnancy increases the volume of distribution and decreases hepatic clearance of theophylline, leading to reduced serum levels. Dose may need to be increased by 20-30% in the second and third trimesters. Monitor serum levels frequently and adjust to maintain therapeutic range. Postpartum, clearance returns to prepregnancy levels rapidly; reduce dose accordingly.
No dose adjustment routinely recommended; however, increased clearance may require monitoring for therapeutic effect.
PHYLLOCONTIN (sustained-release theophylline) is a bronchodilator with a narrow therapeutic index (5-15 mcg/m L). Monitor trough levels before dose escalation. Cigarette smoking, phenytoin, and rifampin induce metabolism, requiring dose increases. Conversely, cimetidine, ciprofloxacin, and fluvoxamine inhibit metabolism, necessitating dose reductions. Use with caution in hepatic impairment, heart failure, and elderly patients due to reduced clearance.
Accurbron (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L. Hepatic metabolism is highly variable; monitor levels closely in patients with liver impairment, heart failure, or those on interacting drugs. Smoking induces metabolism, requiring higher doses. Use with caution in elderly and patients with seizure disorders or peptic ulcer disease. Do not crush or chew extended-release tablets.
Take this medication exactly as prescribed, usually every 12 hours, with or without food.,Do not crush or chew the extended-release tablets; swallow them whole.,Avoid smoking and avoid changing your smoking habits while on this medication, as it affects the drug level.,Limit or avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity such as nausea, vomiting, insomnia, jitteriness, or rapid heartbeat to your healthcare provider immediately.,Do not change your dose or stop taking this medication without consulting your doctor.
Take exactly as prescribed; do not change dose without doctor approval.,Do not crush or chew sustained-release tablets.,Avoid excessive intake of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report any symptoms of toxicity: persistent nausea, vomiting, insomnia, rapid heartbeat, seizures.,Smoking or quitting smoking can affect theophylline levels; inform your doctor about any changes in smoking habits.,Keep regular appointments for blood tests to monitor drug levels.,Avoid taking other medications, including over-the-counter drugs and herbal supplements, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHYLLOCONTIN vs ACCURBRON, answered by our medical review team.
PHYLLOCONTIN is a Xanthine Bronchodilator that works by Sustained-release theophylline; nonselective phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase activator. Bronchodilation via relaxation of bronchial smooth muscle; also reduces airway hyperresponsiveness and inflammation.. ACCURBRON is a Methylxanthine Bronchodilator that works by Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors (M1-M3), reducing vagal tone and bronchoconstriction. Albuterol is a beta2-adrenergic agonist that stimulates adenylate cyclase, increasing c AMP and causing bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHYLLOCONTIN and ACCURBRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHYLLOCONTIN is: For chronic obstructive pulmonary disease and asthma: initial dose 225 mg orally twice daily; may increase to 450 mg twice daily. Based on theophylline, target serum concentration 5-15 mcg/m L.. The standard adult dose of ACCURBRON is: Acetylcysteine 600 mg orally once daily, or 200 mg orally three times daily. Also available as 10% or 20% solution for inhalation: 3-5 m L of 20% solution or 6-10 m L of 10% solution nebulized three to four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHYLLOCONTIN and ACCURBRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHYLLOCONTIN is classified as Category C. Teratogenic risk profile: Theophylline (active ingredient in Phyllocontin) is Pregnancy Category C. First trimester: Limited data suggest no major teratogenic risk, but animal stud. ACCURBRON is classified as Category C. No adequate human data; animal studies show no evidence of teratogenicity. However, use only if clearly needed during pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.